| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 06/22/2011 | EP2336179A1 Stabilized single domain antibodies |
| 06/22/2011 | EP2336177A1 Antibodies to DKK-1 |
| 06/22/2011 | EP2336176A1 Antibodies directed against hepatitis c virus e1e2 complex, and their epitopes |
| 06/22/2011 | EP2336174A2 Human monoclonal antibodies against Hendra and Nipah viruses |
| 06/22/2011 | EP2336168A1 Novel protein and method for producing the protein |
| 06/22/2011 | EP2336151A1 Replikin peptides and uses thereof |
| 06/22/2011 | EP2336150A2 Replikin peptides and uses thereof |
| 06/22/2011 | EP2336149A1 Protein purification method |
| 06/22/2011 | EP2336147A2 A beta immunogenic peptide carrier conjugates and methods of producing same |
| 06/22/2011 | EP2335736A1 Pharmaceutical composition utilising combinations of variants of the gonadotropin-liberating hormone (gnrh) as immunogen |
| 06/22/2011 | EP2335732A2 Multiple-variable dose regimen for treating TNF-alpha-related disorders |
| 06/22/2011 | EP2335731A2 Multiple-variable dose regimen for treating TNF-alpha-related disorders |
| 06/22/2011 | EP2335730A1 Fusion polypeptides and their use for prevention and treatment of cancer |
| 06/22/2011 | EP2335729A2 Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies |
| 06/22/2011 | EP2335728A1 Specific binding proteins and uses thereof |
| 06/22/2011 | EP2335727A2 Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody |
| 06/22/2011 | EP2335726A1 Fusion molecules and methods for treatment of immune diseases |
| 06/22/2011 | EP2335725A1 High concentration antibody and protein formulations |
| 06/22/2011 | EP2335724A1 Immunisation against chlamydia trachomatis |
| 06/22/2011 | EP2335723A1 Immunisation against chlamydia trachomatis |
| 06/22/2011 | EP2335721A1 Streptavidin and Biotin-based antigen delivery system |
| 06/22/2011 | EP2335720A1 Autologous T-cell vaccines materials and methods |
| 06/22/2011 | EP2335719A1 Use of hemojuvelin fusion proteins to regulate hepcidin-mediated iron metabolism |
| 06/22/2011 | EP2335717A1 PAR-1 antagonists for use in the treatment or prevention of influenza virus type a infections |
| 06/22/2011 | EP2335689A1 Method of manufacturing nucleic acid micropheres |
| 06/22/2011 | EP2334826A2 Method of detection and diagnosis of oral and nasopharyngeal cancers |
| 06/22/2011 | EP2334823A1 Methods and compositions for diagnosing and treating a colorectal adenocarcinoma |
| 06/22/2011 | EP2334706A1 Identification of a conserved inner core oligosaccharide region of moraxella catarrhalis lipopolysaccharide as a vaccine antigen |
| 06/22/2011 | EP2334702A2 Methods for inhibiting ocular angiogenesis |
| 06/22/2011 | EP2334694A1 Viral polypeptides and methods |
| 06/22/2011 | EP2334379A2 Host cell kinases as targets for antiviral therapies against hcv infection |
| 06/22/2011 | EP2334332A2 Novel compositions and adjuvants |
| 06/22/2011 | EP2334331A1 Anti-notch2 antibodies and methods of use |
| 06/22/2011 | EP2334330A2 Anti-cd147 antibodies, methods, and uses |
| 06/22/2011 | EP2334329A1 Immunoenhancer-linked oligomeric hiv vaccines |
| 06/22/2011 | EP2334328A1 Methods for purification of viruses |
| 06/22/2011 | EP2334327A1 West nile virus vaccine |
| 06/22/2011 | EP2334326A2 Mimotopes of alpha-synuclein and vaccines thereof for the treatment of neurodegenerative disorders |
| 06/22/2011 | EP2334325A1 Process for treatment of rheumatoid arthritis, tremors/parkinson's disease, multiple sclerosis and non-viral based cancers |
| 06/22/2011 | EP2334311A2 Non-typeable haemophilus influenzae vaccines and their uses |
| 06/22/2011 | EP2334303A1 Tyrosine kinase receptor tyro3 as a therapeutic target in the treatment of cancer |
| 06/22/2011 | EP2132228B1 Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
| 06/22/2011 | EP2117590B1 Non-specific immunostimulating agents |
| 06/22/2011 | EP2094295B1 Method for the diagnosis and/or monitoring of invasive aspergillosis |
| 06/22/2011 | EP1951300B1 Changing th1/th2 balance in split influenza vaccines with adjuvants |
| 06/22/2011 | EP1836226B1 Antibodies against il-13 receptor alpha 1 and uses thereof |
| 06/22/2011 | EP1827488B1 Composition comprising phosphatidyl serine and an antigen or allergen and the use thereof |
| 06/22/2011 | EP1724342B1 Process for preparing variant of erysipelothrix rhusiopathiae surface protective antigen in e. coli |
| 06/22/2011 | EP1642132B1 Glycoconjugates and their use as potential vaccines against infection by shigella flexneri |
| 06/22/2011 | EP1613349B1 Immunogenic recombinant antibody |
| 06/22/2011 | EP1506007B1 Mucosal combination vaccines for bacterial meningitis |
| 06/22/2011 | EP1419240B1 Production and use of human cd124 and cd116 positive tumour cell lines in the production of allogenic or semi-allogenic immunotherapy agents |
| 06/22/2011 | EP1324771B1 Therapeutic and tolerance inducing antibodies |
| 06/22/2011 | EP1204683B1 Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof |
| 06/22/2011 | DE102009056871A1 Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben Vaccine adjuvants and to improved methods for the preparation thereof |
| 06/22/2011 | CN1739029B Prion protein ligands and methods of use |
| 06/22/2011 | CN1560078B Tumor antigen based on products of the tumor suppressor gene WT1 |
| 06/22/2011 | CN1244896B Non-M, non-O, HIV-1 strains, fragments and applications |
| 06/22/2011 | CN102105787A Methods for predicting patient response to modulation of the co-stimulatory pathway |
| 06/22/2011 | CN102105166A Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof |
| 06/22/2011 | CN102105165A Compositions and methods of use of ORF 554 from beta hemolytic streptococcal strains |
| 06/22/2011 | CN102105163A Chloramphenicol acetyl transferase (CAT)-defective somatostatin fusion protein and uses thereof |
| 06/22/2011 | CN102105148A Therapeutic combination comprising an AURORA kinase inhibitor and antiproliferative agents |
| 06/22/2011 | CN102101888A Novel polypeptide for resisting tumors caused by EB (Epstein-Barr) viruses, and application and preparation method thereof |
| 06/22/2011 | CN102100916A Freeze-drying liposome and preparation method and application thereof |
| 06/22/2011 | CN102100911A Preparation method of Cynoglossus semilaevis vibrio anguillarum vaccine |
| 06/22/2011 | CN102100910A Method for producing viral vaccines |
| 06/22/2011 | CN102100909A Preparation method of loach vibrio cholerae vaccine |
| 06/22/2011 | CN101456904B Rhamnose bacterium lacticum Pr2 peptide and coding gene thereof, separation method and application |
| 06/22/2011 | CN101455846B Tuberculosis gene vaccine assembled by chitosan delivery system and preparation method and use thereof |
| 06/22/2011 | CN101327315B Use of maltose binding protein as immunopotentiator |
| 06/22/2011 | CN101044247B Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer |
| 06/21/2011 | US7964711 Compositions comprising polynucleotides encoding TACI-immunoglobulin fusion proteins and methods for producing the same |
| 06/21/2011 | US7964707 Anti-IL2 antibodies |
| 06/21/2011 | US7964703 DNAX Cytokine Receptor Subunits (DCRS) 5 cytokine receptors modulators; multiple sclerosis, rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, diabetes, psoriasis, sepsis or in allogeneic transplant; chronic Th1 mediated disease |
| 06/21/2011 | US7964576 Anti-arthropod vector vaccines, methods of selecting and uses thereof |
| 06/21/2011 | US7964573 Using presence of single nucleotide polymorphism in transient receptor potential channel gene(TRPC) as diagnostic/prognostic tool in detecting idiopathic pulmonary arterial hypertension (IPAH) |
| 06/21/2011 | US7964567 Monomethylvaline compounds capable of conjugation to ligands |
| 06/21/2011 | US7964566 Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases |
| 06/21/2011 | US7964400 Immune potentiating compositions of cancer cells |
| 06/21/2011 | US7964398 Modified vaccinia ankara virus variant and cultivation method |
| 06/21/2011 | US7964397 Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions |
| 06/21/2011 | US7964396 Modified vaccinia ankara virus variant and cultivation method |
| 06/21/2011 | US7964395 Modified vaccinia ankara virus variant and cultivation method |
| 06/21/2011 | US7964375 Polynucleotides encoding human EPO-FC fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo |
| 06/21/2011 | US7964374 Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (MVA) |
| 06/21/2011 | US7964366 Methods and compositions for detection of Ehrlichia chaffeensis (VLPT) |
| 06/21/2011 | US7964200 Methods and compositions for immunizing against Chlamydia infection |
| 06/21/2011 | US7964199 Therapeutic composition comprising a botulinum neurotoxin |
| 06/21/2011 | US7964198 Production of vaccines |
| 06/21/2011 | US7964197 Pathogen for bacterial poultry disease |
| 06/21/2011 | US7964196 Self-assembling nanoparticle drug delivery system |
| 06/21/2011 | US7964195 Using immunoglobulin which preferentially binds cancer specific antigen (OVR110) as treatment for head and neck or endometrial cancer |
| 06/21/2011 | US7964194 Administering antibodies or antigen-binding fragments which bind mammalian chemokines |
| 06/21/2011 | US7964193 Antibodies against interleukin-1 β |
| 06/21/2011 | US7964192 Prevention and treatment of amyloidgenic disease |
| 06/21/2011 | US7964191 Compositions and methods for the treatment of ophthalmic disease |
| 06/21/2011 | US7964190 Administering mixtures of antibodies and tumor necrosis factors, immunosuppressants, antibiotics, antiinflammatory agents, cytokines, angiogenesis inhibitors or fibroblast growth factors; prophylaxis of graft versus host disease |
| 06/21/2011 | US7964187 Sensitization of chemotherapeutic agent resistant neoplastic cells with a virus |
| 06/21/2011 | US7964186 modified adenovirus containing mutation in or lacks the virus associated RNA gene, modified HSV, vaccinia virus and parapoxvirus; Ras-activated pathway; neoplasm; immunosuppressant |